<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62055">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01882036</url>
  </required_header>
  <id_info>
    <org_study_id>0908M70742</org_study_id>
    <nct_id>NCT01882036</nct_id>
  </id_info>
  <brief_title>Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Effects of Roux-en-Y Gastric Bypass on Mitochondrial Dysfunction and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of this proposal is to define the mechanism by which bariatric surgery acutely
      improves glucose homeostasis.  Our central hypothesis is that drastically reduced caloric
      intake early after Roux-en-Y Gastric Bypass (RYGB) improves the pro-inflammatory profile of
      macrophages, which in turn improves insulin sensitivity and glucose homeostasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Measure homeostasis model assessment i.e. estimated change in insulin resistance (HOMA-IR) index</measure>
    <time_frame>Seven days before and 10 days following RYGB or hypocaloric diet similar to RYGB patients</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>RYGB with matched hypocaloric diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypocaloric Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux en Y Gastric Bypass</intervention_name>
    <description>Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days</description>
    <arm_group_label>RYGB with matched hypocaloric diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypocaloric diet</intervention_name>
    <description>Hypocaloric liquid diet for 10 days</description>
    <arm_group_label>Hypocaloric Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria::

          1. Candidate for RYGB gastric bypass with insurance approval.

          2. Willing to accept randomization to either immediate surgery, or delayed surgery after
             diet study.

          3. Willing to undergo two sessions of testing before, and ten days after surgery (or
             initiation of dietary intervention).

          4. BMI 35-45kg/m2

          5. Pre-diabetes (ADA criteria) or T2DM with HbA1c&lt; 8%.

        Exclusion criteria:

          1. T1DM.

          2. Serious illness such as cancer, active chronic infection, cardiovascular disease
             greater that New York Heart Association class 2, chronic renal failure, chronic lung
             disease.

          3. Inflammatory or celiac intestinal disease.

          4. Untreated thyroid disease.

          5. Serious psychiatric disease.

          6. Excessive alcohol use.

          7. Illicit drug use. -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JOYCE L SCHONE, RD</last_name>
    <phone>612-273-4860</phone>
    <email>jschone1@fairview.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanley E E. Williams, PhD</last_name>
    <phone>612 6253265</phone>
    <email>willi004@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce L Schone, RD</last_name>
      <phone>612-273-4860</phone>
      <email>jschone1@fairview.org</email>
    </contact>
    <contact_backup>
      <last_name>Stanley E E. Williams, PhD</last_name>
      <phone>612 6253265</phone>
      <email>willi004@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sayeed Ikramuddin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 17, 2013</lastchanged_date>
  <firstreceived_date>June 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
